Position of Design & Copyright Protection in Pharmaceutical Industry

Q: What is law available for the protection of graphics, contents, visual elements & creativity available on the packing material and novel appearance of the pharma related products.
– Ashok Kumar
A: Except so many other factors, the pharma products are known with their brands and style of packing material. The exclusive, unique & creative designs of the products their containers and packing material play an important role in the recognition of the products which do not only keep the products in a different track from others but contribute to the goodwill of the brands and company also. For such kind of arrangements, the design of the products should be different from others and should be protected by the design registration. Here, the Industrial Design refers to the “Design” defined under the “Design Act, 2000” which is further registered under the same Act. As per the provision of this Act, “design” means only the features of shape, configuration, pattern, ornament or composition of lines or colors applied to any article whether in two dimensional or three dimensional or in both forms, by any industrial process or means, whether manual, mechanical or chemical, separate or combined, which in the finished article appeal to and are judged solely by the eye. The design of any pharma product to be registrable under the act should be new and original.

The copyright protection also has its place in pharma sector in the same way as design does through the protection of graphics, contents, visual elements, text material & creativity available on the packing material of the pharma products. Protecting through copyright registration, one can keep his packing material, outer carton’s design and appearance of pharma related products safe from being infringed which results from unauthorized use, copy or duplication.

Dr. Javed Hasan,
Advocate (High Court, Delhi) Through,
Lex Intellectia Attorneys for, Drugs & IPR Laws
Email : lexintellectia@gmail.com
Phone : 9818522970

Related Posts

Aurobindo Pharma Rs 800 Cr Buyback Opens Apr 23

New Delhi:  Aurobindo Pharma Ltd on Tuesday said it has set April 23 as the opening date for its Rs 800 crore buyback offer. The closing date for the buyback…

Boehringer Ingelheim launches AI centre for pharma research in London

Bengaluru: German drugmaker Boehringer Ingelheim is launching a ​centre for artificial ​intelligence and machine learning in London, it said ​on Monday, as it seeks to expand its AI capabilities in…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Aurobindo Pharma Rs 800 Cr Buyback Opens Apr 23

Aurobindo Pharma Rs 800 Cr Buyback Opens Apr 23

Boehringer Ingelheim launches AI centre for pharma research in London

Boehringer Ingelheim launches AI centre for pharma research in London

Pharma exports rose 2% to over $31 billion in FY26 despite sharp decline in March

Pharma exports rose 2% to over $31 billion in FY26 despite sharp decline in March

Centre Urges States To Enforce Clinical Establishments Act & Standardise Hospital Rates

Centre Urges States To Enforce Clinical Establishments Act & Standardise Hospital Rates

Piramal, Ajinomoto team on ADC development and manufacturing

Piramal, Ajinomoto team on ADC development and manufacturing

Aurobindo Pharma Gets USFDA Nod for Glycerol Liquid

Aurobindo Pharma Gets USFDA Nod for Glycerol Liquid